Merck and Co Inc   (MRK)
Other Ticker:  
Price: $93.5500 $1.46 1.585%
Day's High: $94.08 Week Perf: 1.33 %
Day's Low: $ 92.45 30 Day Perf: 8.49 %
Volume (M): 11,757 52 Wk High: $ 94.56
Volume (M$): $ 1,099,877 52 Wk Avg: $79.25
Open: $92.45 52 Wk Low: $15.32

 Market Capitalization (Millions $) 237,177
 Shares Outstanding (Millions) 2,535
 Employees 71,000
 Revenues (TTM) (Millions $) 52,525
 Net Income (TTM) (Millions $) 14,189
 Cash Flow (TTM) (Millions $) 1,603
 Capital Exp. (TTM) (Millions $) 4,298

Merck And Co Inc
Merck & Co., Inc., is a global research-driven pharmaceutical products company that discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures. The Company sells its products primarily to drug wholesalers and retailers, hospitals, clinics, government agencies and managed health care providers such as health maintenance organizations and other institutions. The Company’s professional representatives communicate the effectiveness, safety and value of its products to health care professionals in private practice, group practices and managed care organizations.

The Company’s products include therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Among these are atherosclerosis products, of which Zocor (simvastatin) is the largest-selling; hypertension/heart failure products, the most significant of which are Cozaar (losartan potassium), Hyzaar (losartan potassium and hydrochlorothiazide), and Vasotec (enalapril maleate); anti-inflammatory/analgesics, which include Vioxx (rofecoxib) and Arcoxia (etoricoxib), agents that specifically inhibit the COX-2 enzyme, which is responsible for pain and inflammation (“coxibs”); an osteoporosis product, Fosamax (alendronate sodium), for treatment and prevention of osteoporosis; a respiratory product, Singulair (montelukast sodium), a leukotriene receptor antagonist for treatment of asthma and for relief of symptoms of seasonal allergic rhinitis; vaccines/biologicals, of which M-M-R II (measles, mumps and rubella virus vaccine live), Varivax (varicella virus vaccine live), a live virus vaccine for the prevention of chickenpox, and Recombivax HB (hepatitis B vaccine [recombinant]) are the largest-selling; anti-bacterial/anti-fungal products, which includes Primaxin (imipenem and cilastatin sodium), as well as newer products Cancidas (caspofungin acetate) and Invanz (ertapenem sodium); ophthalmologicals, of which Cosopt (dorzolamide hydrochloride and timolol maleate ophthalmic solution) and Trusopt (dorzolamide hydrochloride ophthalmic solution) are the largest-selling; a urology product, Proscar (finasteride), for treatment of symptomatic benign prostate enlargement; and HIV products, which include Crixivan (indinavir sulfate) and Stocrin (efavirenz), for the treatment of human immunodeficiency viral infection in adults.

Other primarily includes Maxalt (rizatriptan benzoate), for the treatment of acute migraine headaches in adults, Propecia (finasteride), for the treatment of male pattern hair loss, and other non-promoted products and pharmaceutical and animal health supply sales to the Company’s joint ventures and revenue from the Company’s relationship with AstraZeneca LP, primarily relating to sales of Nexium (esomeprazole magnesium) and Prilosec (omeprazole).

Our business is preserving and improving human life and animal health. All of our actions must be measured by our success in achieving this goal. Above all, we value our ability to serve patients who can benefit from the appropriate use of our products and services. We are dedicated to providing the highest level of professional excellence and health delivery systems. We strive to identify the most critical needs of health care professionals and consumers, and we devote our resources to meeting those needs.

Competition — The markets in which the Company’s pharmaceutical business is conducted are highly competitive and often highly regulated. Global efforts toward health care cost containment continue to exert pressure on product pricing and access.

Such competition involves an intensive search for technological innovations and the ability to market these innovations effectively. With its long-standing emphasis on research and development, the Company is well prepared to compete in the search for technological innovations. Additional resources to meet competition include quality control, flexibility to meet customer specifications, an efficient distribution system and a strong technical information service. The Company is active in acquiring and marketing products through joint ventures and licenses and has been refining its sales and marketing efforts to further address changing industry conditions. To enhance its product portfolio, the Company continues to pursue external alliances, from early-stage to late-stage product opportunities, including joint ventures and targeted acquisitions. However, the introduction of new products and processes by competitors may result in price reductions and product replacements, even for products protected by patents. For example, the number of compounds available to treat diseases typically increases over time and has resulted in slowing the growth in sales of certain of the Company’s products.

   Company Address: 126 East Lincoln Avenue Rahway 7065 NJ
   Company Phone Number: 740-4000   Stock Exchange / Ticker: NYSE MRK
   MRK is expected to report next financial results on August 08, 2022.

Customers Net Income grew by MRK's Customers Net Profit Margin fell to

2.52 %

4.49 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

Year to Date Decrease / Increase
ABT   -18.56%    
BMY        23.13% 
JNJ        3.17% 
LLY        9.98% 
PFE   -7.38%    
ABBV        11.51% 
ACT        10.65% 
BIIB   -18.22%    
GILD   -12.04%    
• View Complete Report

Gas Transporter Of The South Inc

Gas Transporter Of The South Inc announced top-line remained unaltered in the financial fourth quarter of 2021

In the financial fourth quarter of 2021 Gas Transporter Of The South Inc eps remained unchanged of $0.73 per share compared to $0.73 a year ago and from $0.00 per share from the previous quarter.

Analog Devices Inc.

Analog Devices Inc reported an outstanding 78.89%, Sales advance in the financial period ending Apr 30 2022

In the financial period ending Apr 30 2022 Analog Devices Inc profits soared by 30.7 % of $1.49 per share compared to $1.14 a year ago and eps more than doubled by 181.13 % from $0.53 per share from the previous quarter.

Hawkins Inc.

Hawkins Inc declared a top-line gain by very healthy 86.88% in the fourth quarter of 2022

Hawkins Inc delivered very strong results in the fourth quarter of 2022, where Sales soared by 86.88% to $267.10 millions, while company's earnings per share soared by 304.82 % to $0.61 per share, from the same quarter a year ago.

Allegro Microsystems Inc.

Allegro Microsystems Inc declared in the fourth quarter of 2022

For the fourth quarter of 2022 Allegro Microsystems Inc earnings turn positive at $0.13 per share, compared to results of $-0.01 per share a year ago quarter, In the previous quarter company realized $0.17 per share.

Braskem Sa

Sales and Earnings Unchanged

Braskem Sa announced operating deficit of $0 millions, in the fourth quarter of 2020, a change from the operating loss of $0 millions, recorded in the same quarter a year ago.


Merck And Co Inc 's Segments
 Segment    0.57 % of total Revenue
 Segment    6.48 % of total Revenue
 Segment    1.54 % of total Revenue
 Segment    2.06 % of total Revenue
 Segment    0.42 % of total Revenue
 Segment    3.86 % of total Revenue
 Segment    0.77 % of total Revenue
 Segment    4.52 % of total Revenue
 Segment    10.38 % of total Revenue
 Segment    1.42 % of total Revenue
 Segment    59.33 % of total Revenue
Merck Pharmaceutical
 Segment    91.34 % of total Revenue
 Segment    11.28 % of total Revenue
All Other
 Segment    8.66 % of total Revenue
• View Complete Report
  Company Estimates  
  Revenue Outlook
Merck And Co Inc does not provide revenue guidance.

Earnings Outlook
Braskem Sa does not provide earnings estimates.

Geographic Revenue Dispersion
United States 40.42 %
EMEA 31.19 %
Japan 8.22 %
Other 3.36 %
Asia Pacific 9.35 %
Latin America 7.46 %


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

HLG's Profile

Stock Price

HLG's Financials

Business Description


Charts & Quotes

HLG's News


HLG's Competitors

Customers & Markets

Economic Indicators

HLG's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength


Largest Companies

Management Effectivness


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries






About us


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071